StockData

Autolus Therapeutics vs Immunocore

AUTL and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AUTL and IMCR compare

Immunocore is the larger company, worth 4.9 times as much as Autolus Therapeutics ($1.4B against $290M).

Autolus Therapeutics grew revenue faster over the last twelve months (292% versus 21.0% for Immunocore).

Immunocore keeps more of each dollar of sales as profit, with a net margin of −4.2% compared with −239% at Autolus Therapeutics.

Immunocore scores higher on the StockData Score (7 against 5 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAUTLIMCR
Size and price
Market cap$290M$1.4B
Share price$1.09$27.81
Change, 1 year−20.4%−22.6%
Change, 5 years−82.6%−23.6%
Beta (5Y)3.470.19
Employees754524
StockData Score
Total score57 (better)
Valuation score11
Growth score3 (better)2
Performance score03 (better)
Health score11
Dividend score00
Valuation
P/S2.5× (better)3.3×
P/B3.9×3.4× (better)
FCF yield−80.2%−2.9% (better)
Fair value$1.36$32.29
Margin of safety19.8% (better)13.9%
Growth
Revenue growth (TTM)292% (better)21.0%
Profitability
Gross margin15.7%98.9% (better)
Operating margin−211%−5.2% (better)
Net margin−239%−4.2% (better)
FCF margin−198%−9.6% (better)
Return on equity−133%−4.5% (better)
Financial health
Interest coverage−5.9×−1.8× (better)
Current ratio4.89 (better)4.47
Altman Z-score−4.601.40 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions49.7%102%
Held by insiders24.6%15.5%
Insider net buying, 12 months−$15.7K (better)−$1.9M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.